Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 208 of 6351
-
A spoonful of olive oil before lung surgery: a new shield against a rare complication?
Prevention Recruiting nowChylothorax is a rare but serious complication after lung cancer surgery and mediastinal lymph node dissection. This multicenter randomized trial will evaluate whether drinking 40 mL of extra-virgin olive oil 4 hours before surgery can reduce the occurrence of chylothorax after c…
Sponsor: Fudan University • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New drug pumitamig takes on nivolumab in stomach cancer showdown
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal aden…
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to spare bladders in cancer patients
Disease control Recruiting nowPeople with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladder. This has a significant impact on peopl…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New RSV drug for babies shows promise in phase 3 trial
Symptom relief Recruiting nowThis is a randomized, double-blind, placebo-controlled, parallel-group trial conducted in infants and young children aged 1 to 36 months with RSV infection. A total of 498 subjects are expected to be enrolled and randomly assigned to the investigational product group or the plac…
Phase 3 • Sponsor: Simcere Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell gel could offer new hope for knee arthritis sufferers
Disease control Recruiting nowTo establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator o…
Phase 3 • Sponsor: Medipost, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for AML: Three-Drug combo aims to boost remission
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of venetoclax combined with azacitidine and mitoxantrone hydrochloride liposome (MVA) versus idarubicin combined with cytarabine (IA) in the treatment of newly diagnosed AML.
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for myeloma: experimental drug takes on standard combo
Disease control Recruiting nowThe purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Phase 3 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill could keep early breast cancer from coming back
Disease control Recruiting nowThe study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antiviral pill aims to shorten RSV symptoms in vulnerable adults
Disease control Recruiting nowRespiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia, and affect the cardiovascular system, central nervous…
Phase 2/3 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to boost pancreatic cancer surgery success
Disease control Recruiting nowTo explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
Phase 3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancer
Disease control Recruiting nowThis illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates pre…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New chemo cocktail aims to boost pancreatic cancer surgery success
Disease control Recruiting nowThis phase II trial tests how well liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) before surgery works in treating patients with pancreatic ductal adenocarcinoma that is close to major blood vessels, but is still potentially removable by surgery (bor…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control Recruiting nowopen-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinica…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2. The study is designed as a biomarker-enriched, open-label, non-r…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New ALS drug trial aims to slow disease progression
Disease control Not yet recruitingThe objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
Phase 2/3 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to save kidneys in rare autoimmune disease
Disease control Not yet recruitingANCA-associated vasculitis (AAV) is a rare auto-immune disease, with high mortality in the absence of treatment. There is still an unmet need to define new treatment strategies to reduce drug side effects, as well as to reverse rare cases of refractory AAV and improve the kidney …
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug TQB2102 enters phase 3 trial
Disease control Not yet recruitingThis is a Phase III, randomized, open-label, active-controlled, multicenter study designed to evaluate the efficacy and safety of Injection TQB2102 compared with investigator's choice of treatment in subjects with Human Epidermal Growth Factor Receptor 2 (HER2) ImmunoHistoChemist…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can more radiation beat lung cancer? new trial aims to find out
Disease control Recruiting nowThis is a phase III clinical trial that aims to evaluate whether increasing the dose of radiotherapy given twice a day can improve treatment outcomes in patients with localized small cell lung cancer (SCLC). All patients will receive standard chemotherapy with cisplatin and etopo…
Phase 3 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to improve leukemia treatment in young adults
Disease control By invitation onlyThis is a phase II/III, multicenter, randomized, three-arm, open-label, parallel controlled trial. The primary objective of this study is to compare the 2-years EFS rate of the LDA, LHAA, and DA regimens in newly diagnosed patients with low-risk acute myeloid leukemia who are eli…
Phase 2/3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a triple therapy help rectal cancer patients avoid a colostomy bag?
Disease control Not yet recruitingThe goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs). The study aims to increase the chance of making the tumor disappear completely (call…
Phase 2 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC